These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36254892)

  • 41. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.
    Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V
    JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
    Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B
    PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
    Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
    JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.
    Turbyfill C; Adams K; Tenforde MW; Murray NL; Gaglani M; Ginde AA; McNeal T; Ghamande S; Douin DJ; Keipp Talbot H; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Clark Files D; Hager DN; Shehu A; Prekker ME; Frosch AE; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Lauring AS; Khan A; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; June Gordon A; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Rhoads JP; Lindsell CJ; Hart KW; McMorrow M; Surie D; Self WH; Patel MM
    Vaccine; 2022 Nov; 40(48):6979-6986. PubMed ID: 36374708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, Spain.
    Mallah N; Pardo-Seco J; Ares-Gómez S; López-Pérez LR; González-Pérez JM; Rosón B; Otero-Barrós MT; Durán-Parrondo C; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Gómez-Carballa A; Salas A; Martinón-Torres F
    Pediatr Allergy Immunol; 2023 Oct; 34(10):e14037. PubMed ID: 37877845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
    Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
    Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Bennett JC; Luiten KG; O'Hanlon J; Han PD; McDonald D; Wright T; Wolf CR; Lo NK; Acker Z; Regelbrugge L; McCaffrey KM; Pfau B; Stone J; Schwabe-Fry K; Lockwood CM; Guthrie BL; Gottlieb GS; Englund JA; Uyeki TM; Carone M; Starita LM; Weil AA; Chu HY
    Vaccine; 2024 Feb; 42(6):1332-1341. PubMed ID: 38307746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
    Link-Gelles R; Levy ME; Gaglani M; Irving SA; Stockwell M; Dascomb K; DeSilva MB; Reese SE; Liao IC; Ong TC; Grannis SJ; McEvoy C; Patel P; Klein NP; Hartmann E; Stenehjem E; Natarajan K; Naleway AL; Murthy K; Rao S; Dixon BE; Kharbanda AB; Akinseye A; Dickerson M; Lewis N; Grisel N; Han J; Barron MA; Fadel WF; Dunne MM; Goddard K; Arndorfer J; Konatham D; Valvi NR; Currey JC; Fireman B; Raiyani C; Zerbo O; Sloan-Aagard C; Ball SW; Thompson MG; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(29):931-939. PubMed ID: 35862287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19.
    Tartof SY; Slezak JM; Frankland TB; Puzniak L; Hong V; Ackerson BK; Stern JA; Zamparo J; Simmons S; Jodar L; McLaughlin JM
    JAMA Intern Med; 2024 Aug; 184(8):932-940. PubMed ID: 38913355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
    Hall V; Foulkes S; Insalata F; Kirwan P; Saei A; Atti A; Wellington E; Khawam J; Munro K; Cole M; Tranquillini C; Taylor-Kerr A; Hettiarachchi N; Calbraith D; Sajedi N; Milligan I; Themistocleous Y; Corrigan D; Cromey L; Price L; Stewart S; de Lacy E; Norman C; Linley E; Otter AD; Semper A; Hewson J; D'Arcangelo S; Chand M; Brown CS; Brooks T; Islam J; Charlett A; Hopkins S;
    N Engl J Med; 2022 Mar; 386(13):1207-1220. PubMed ID: 35172051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19 Vaccine Effectiveness Against Omicron Infection and Hospitalization.
    Piché-Renaud PP; Swayze S; Buchan SA; Wilson SE; Austin PC; Morris SK; Nasreen S; Schwartz KL; Tadrous M; Thampi N; Wilson K; Kwong JC;
    Pediatrics; 2023 Apr; 151(4):. PubMed ID: 36866446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
    Rane MS; Robertson MM; Kulkarni SG; Frogel D; Gainus C; Nash D
    Vaccine; 2023 Jan; 41(4):989-998. PubMed ID: 36588007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults.
    Lee N; Nguyen L; Austin PC; Brown KA; Grewal R; Buchan SA; Nasreen S; Gubbay J; Schwartz KL; Tadrous M; Wilson K; Wilson SE; Kwong JC
    Clin Infect Dis; 2024 May; 78(5):1372-1382. PubMed ID: 38001037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study.
    Chung H; Austin PC; Brown KA; Buchan SA; Fell DB; Fong C; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
    Open Forum Infect Dis; 2022 Sep; 9(9):ofac449. PubMed ID: 36147595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.